Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Published byHelena Sullivan Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists."— Presentation transcript:

1 Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists engaged in MS DMT guideline development Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists engaged in MS DMT guideline development The proportion of persons with MS (n = 2,156) and guideline panelists (n = 18) designating an outcome as first-, second-, or third-highest priority (priority outcomes) when selecting an MS DMT is depicted (rank-ordered from most to least common responses). QoL = quality of life. Published with permission from Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018;90:777–788. doi: /WNL Gregory S. Day et al. Neurol Clin Pract 2018;8: © 2018 American Academy of Neurology

Download ppt "Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists."

Similar presentations

Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force by.

Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force by.
Copyright © 2017 American Academy of Pediatrics.

Copyright © 2017 American Academy of Pediatrics.
Figure Flow of funds for a 340B agreement for fingolimod

Figure Flow of funds for a 340B agreement for fingolimod
Figure EDSS, FS scores, and Modified MSFC scores

Figure EDSS, FS scores, and Modified MSFC scores
Figure 3 Proportion of patients for whom NEDA

Figure 3 Proportion of patients for whom NEDA
Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.

Figure 2 Orbital MRI findings One-third of myelin oligodendrocyte glycoprotein antibody–positive patients revealed extensive enhancement patterns that.
Figure 1 Patient flow diagram

Figure 1 Patient flow diagram
Figure 1 Clinical correlates of neurodegeneration in MS

Figure 1 Clinical correlates of neurodegeneration in MS
Figure 3 JCV index changes in JCV+ patients

Figure 3 JCV index changes in JCV+ patients
Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.
Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.

Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.
Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.

Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 4 Relationship of thickness of retinal layers to quality of life and low-contrast visual acuity Scatter plot and fitted linear regression line showing.

Figure 4 Relationship of thickness of retinal layers to quality of life and low-contrast visual acuity Scatter plot and fitted linear regression line showing.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.

Figure 1 Dominant and recessive missense and nonsense variants in neurofilament light (NEFL)‏ Dominant and recessive missense and nonsense variants in.
Figure 2 Forest plots for subgroup analyses

Figure 2 Forest plots for subgroup analyses
Figure 3 Temporal trends in FALS incidence

Figure 3 Temporal trends in FALS incidence
Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.

Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.
Figure 1 White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)‏ White matter lesion central vein visibility in MS.

Figure 1 White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)‏ White matter lesion central vein visibility in MS.

Similar presentations

Ads by Google